MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced …
Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors Bavarian Nordic A/S (OMX: BAVA, …
Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …
Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that results …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
